Bioinvent International AB;University of Southampton
发明人:
FRENDÉUS, Björn,TEIGE, Ingrid,MÅRTENSSON, Linda,CRAGG, Mark,BEERS, Stephen,ROGHANIAN, Ali,OLDHAM, Robert
申请号：
AU2019207767
公开号：
AU2019207767A1
申请日:
2019.01.10
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
Described is the use of a first antibody molecule that specifically binds FcγRllb via its Fab region, but lacks Fc region or has reduced binding to Fcγ receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on an immune cell, wherein the immune cell is an immune cell that suppresses anti-cancer immunity, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor, and wherein the binding of the second antibody molecule to the receptor on the immune cell causes depletion and/or deactivation of the immune cell in the treatment of an FcγRllb-negative cancer in a patient, as well as pharmaceutical compositions and kits comprising these to antibody molecules, and methods of treating cancer using these two antibodies.
